Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Across the fields of pharmacovigilance (PV) and medical information (MI), companies must continuously evolve to accommodate the latest technology and meet the newest regulations across each country where they manufacture and sell products. At the local affiliate level, maintaining compliant PV and MI models entails a wide variety of requisites, including the following: |
Throughout these processes, it is crucial to maintain consistency and transparency between local and global outfits, particularly when it comes to training and documentation. So how does one ensure these processes run efficiently and compliantly while still managing to reduce costs?
Luckily, there are plenty of innovations that can help bolster smooth collaboration between the global and local level, ensure consistency across affiliates, increase cost savings, improve patient safety, and alleviate high volume strain on local PV teams. A number of these solutions are offered as part of IQVIA’s Local Affiliate Product Services (LAPS):
In the recent whitepaper, “Thinking globally, while acting locally – How to streamline pharmacovigilance and medical information at the affiliate level,” IQVIA leaders, Alisa Hummings, senior director and head of medical information and CEVA services, and Barry Mulchrone, senior director and head of pharmacovigilance oversight and analytics, provide their expert insight into local PV, MI, and risk management challenges and solutions, including those offered as part of the LAPS offering. To learn more about how your PV model can reduce costs and better ensure patient safety, download IQVIA’s comprehensive whitepaper.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Improve the performance of your clinical trials with the power of the IQVIA CORE.
Harness the power of global human expertise combined with automation, artificial intelligence (AI) and machine learning (ML) to design, build and execute end-to-end safety solutions.